Business Wire

TX-LTTS

24.7.2024 11:56:31 CEST | Business Wire | Press release

Share
Digital Engineering Awards Launched by L&T Technology Services, ISG and CNBC TV18

L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a leading global digital engineering and R&D company, today announced the launch of the third annual Digital Engineering Awards, in association with Information Services Group (ISG), a leading global technology research and advisory firm, and business news channel CNBC TV18 in India.

The Digital Engineering Awards recognize and celebrate global engineering excellence and innovation. Nominations are open to all product companies, manufacturers, and OEMs worldwide.

Enterprises and their service providers are invited to submit nominations through September 23, 2024. Winners will be announced during a gala awards celebration on December 7, 2024, in Dallas, Texas, U.S.A.

The latest edition of the Digital Engineering Awards aims to build on the success of the program to date, including that of the 2023 program, which attracted 200-plus nominations from more than 100 leading organizations from around the world. Winners over the last two years include such blue-chip names as AT&T, BMW Group, Caterpillar Inc., Chevron, Delta Airlines, ExxonMobil, GE Healthcare, Honeywell and Microsoft, among others.

For the 2024 program, enterprise award winners will be selected by a global panel of industry experts—including representatives from ISG—in 11 categories, comprising six team awards and five individual awards.

This year’s awards are divided into two segments—Engineering The Change and Engineer At Heart—and spread across the 11 categories. Reflecting the recent dynamic shifts in technology and AI adoption, two new awards have been created: AI Champion (Innovator) of the Year and AI Impact of the Year.

The Awards will be presented at the December 7 gala ceremony in the following categories:

Engineering the Change Team Awards

  • Digital Transformation of the Year
  • Top Sustainability Initiative
  • Digital Engineering Project/Program of the Year
  • Engineering Product of the Year
  • Excellence in Value Realization
  • AI Impact of the Year

Engineer at Heart Individual Awards

  • The Distinguished Digital Engineering Leader
  • The Digital Engineer of the Year
  • The Woman Engineer of the Year
  • The Innovator of the Year
  • AI Innovator of the Year

Click here to submit your nominations
https://www.digitalengineeringawards.com/

About The Digital Engineering Awards

The Digital Engineering Awards bring together industry leaders to recognize outstanding achievements in the R&D domain, and to help global organizations give shape to their transformative ideas. The Awards are produced by L&T Technology Services in association with ISG, with CNBC TV18 as a media partner.

To know more on the Awards, visit our website or contact us.

About L&T Technology Services Ltd

L&T Technology Services Limited (LTTS) is a listed subsidiary of Larsen & Toubro Limited focused on Engineering and R&D (ER&D) services. We offer consultancy, design, development and testing services across the product and process development life cycle. Our customer base includes 69 Fortune 500 companies and 57 of the world’s top ER&D companies, across industrial products, medical devices, transportation, telecom & hi-tech, and the process industries. Headquartered in India, we have over 23,550 employees spread across 22 global design centers, 30 global sales offices and 108 innovation labs as of June 30, 2024. For more information, please visit https://www.LTTS.com/.

About ISG (Information Services Group)

ISG (Information Services Group) (Nasdaq: III) is a leading global technology research and advisory firm. A trusted business partner to more than 900 clients, including more than 75 of the world’s top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including AI and automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs 1,600 digital-ready professionals operating in more than 20 countries—a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry’s most comprehensive marketplace data. For more information, visit www.isg-one.com.

About Network18

Network18 is India's leading media conglomerate, which includes the country’s largest omni-channel news network, consisting of 20 news channels across 16 languages and 4 online news platforms across 13 languages. It is the highest reach TV news network in India, reaching over 175 million people around the country every week with a viewership share of 10.9%. Network18’s digital portfolio is India’s No. 2 digital news/information publisher with over 180 million unique visitors every month.

The network operates some of India’s top news channels such as CNN-News18 (English), News18 India (Hindi), CNBC-TV18 (English) & CNBC Awaaz (Hindi). The regional portfolio of the news network boasts 15 channels such as News18 Uttar Pradesh / Uttarakhand, News18 Bihar / Jharkhand, News18 Madhya Pradesh / Chhattisgarh, News18 Rajasthan, News18 Punjab / Haryana, News18 J&K / Ladakh / Himachal, News18 Assam/NE, News18 Gujarati, News18 Bangla, News18 Odia, News18 Kerala, News18 Kannada, News18 Tamil Nadu, News18 Lokmat and CNBC Bajar.

It is also home to India’s most visited news websites such as News18.com, CNBCTV18.com, Moneycontrol.com, firstpost.com among others. Network18’s latest initiative Local18 (which focuses on hyperlocal content) covers almost 300 districts in India. The group also publishes Forbes in India.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240724486316/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye